論文・技術情報追加のお知らせ

1. Real-World Pharmacovigilance Analysis of Drug-Induced Decreased Cardiac Ejection Function: Evidence from the FAERS Database (2004-2024).

FAERSを用い薬剤性心拍出量低下リスクを解析。抗がん剤等で顕著。

対象DB：FAERS

2. Bridging FDA Adverse Event Reporting System (FAERS) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients.

FAERSデータを用い、薬剤性無菌性髄膜炎の発生状況を包括的に解析。

対象DB：FAERS

3. Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database.

ラブリズマブの副作用をFAERSで解析。感染症や血液疾患に注目。

対象DB：FAERS

4. Strong Signals of Adverse Events in Tyrosine Kinase Inhibitor Therapy for Liver Cancer Treatment.

肝がんのチロシンキナーゼ阻害薬治療における重篤副作用を解析。

対象DB：FAERS

5. Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS.

嚢胞性線維症治療薬ルマカフトル等の市販後安全性をFAERSで評価。

対象DB：FAERS

6. Association between concomitant use of direct oral anticoagulants with antidepressants and an increased risk of hemorrhage: analysis of the food and drug administration adverse event reporting system database.

DOACと抗うつ薬の併用による大出血リスク増加をレセプトで調査。

対象DB：FAERS

7. Risk assessment of drug-associated miscarriage using XGBoost and SHAP explainability: a real-world pharmacovigilance analysis based on the FAERS database.

機械学習を用い薬剤性流産のリスク因子を大規模データから評価。

対象DB：FAERS

8. Drug-associated insomnia and sex-specific disproportionality in the FDA adverse event reporting system (2019-Q1 2025).

薬剤性不眠症の性差をFAERS不均衡解析により詳細に特定。

対象DB：FAERS

9. Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database.

アトピー治療薬トラロキヌマブの副作用をFAERSで解析し評価。

対象DB：FAERS

10. Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database.

インテグラーゼ阻害薬等の副作用をHIV治療の優先順位に基づき解析。

対象DB：FAERS

11. Adverse events associated with use of immunoglobulin in pediatric patients reported to the US Food and Drug Administration Adverse Event Reporting System, 2001-2023.

小児における免疫グロブリン製剤の副作用をFAERSデータで解析。

対象DB：FAERS

12. Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.

セマグルチドによる虚血性視神経症リスクを性別・製剤別に解析。

対象DB：FAERS

13. Evaluation of Anticancer Therapy-Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset.

抗がん剤による腫瘍フレア反応をFAERSに基づき包括的に解析。

対象DB：FAERS

14. Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.

ロイコトリエン受容体拮抗薬とEGPAの関連をFAERS等で解析。

対象DB：FAERS,JADER

15. QT-related adverse events with ondansetron and olanzapine: a real-world FAERS analysis with implications for oncology anti-emetic practice.

オンダンセトロンとオランザピンのQT延長リスクをFAERSで解析。

対象DB：FAERS

16. Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS).

GLP-1受容体作動薬の市販後における副作用の変遷をFAERSで評価。

対象DB：FAERS

17. Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess.

セツキシマブによる皮膚副作用の特徴を複数DBを用いて解析。

対象DB：FAERS

18. Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS.

アテゾリズマブの市販後安全性を複数データベースに基づき解析。

対象DB：FAERS

19. Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

胸腺上皮腫瘍に対する免疫療法の安全性をFAERSを用いて解析。

対象DB：FAERS

20. Safety profile of ticagrelor: an analysis based on literature and database review.

チカグレロルの安全性プロファイルを文献とDBレビューで解析。

対象DB：FAERS

21. Analysis of herpes zoster cases in multiple sclerosis patients treated with disease-modifying drugs: insights from the EudraVigilance database.

多発性硬化症治療薬投与患者における帯状疱疹の発生状況を解析。

対象DB：EudraVigilance

22. Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database.

2種のデング熱ワクチンの市販後安全性をVAERSデータで比較。

対象DB：EudraVigilance

23. Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase.

ウィルソン病治療薬の市販後安全シグナルをFAERS等で検証。

対象DB：VigiBase

24. Sex and age disparities in goserelin safety: a global pharmacovigilance study.

ゴセレリンの安全性における性別および年齢による差異を解析。

対象DB：VigiBase

25. GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation.

ブラジルにおけるGLP-1受容体作動薬の消費・安全・規制の現状。

対象DB：VigiBase

26. Global insights into [(177)Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database.

[(177)Lu]Lu-DOTATATEの安全性を世界規模のデータで解析。

対象DB：VigiBase

27. Innovation in Atrial Fibrillation Treatment and the Paradox of Regional Disparity.

心房細動治療の革新と地域格差のパラドックスに関する調査。

対象DB：DPC

28. Overview of Immunotherapy Administration for Miller Fisher Syndrome in Japan: A Nationwide Retrospective Cohort Study.

日本におけるミラー・フィッシャー症候群への免疫療法実施状況。

対象DB：DPC

29. Novel predictive score for sleep disordered breathing in Asians: the Nagahama study.

アジア人における睡眠呼吸障害の新規予測スコアの開発。

対象DB：JMDC

30. Prognostic Significance of the Estimated Small Dense Low-Density Lipoprotein Cholesterol Levels in Predicting the Incidence of Coronary Artery Disease: The Nagahama Study and Shizuoka Kokuho Database Study.

小粒子低比重リポ蛋白コレステロール値の冠動脈疾患での予後意義。

対象DB：NDB

31. Real-World Treatment Patterns Before and After Metastatic Castration-Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital-Based, Multicenter Database.

日本における転移性去勢抵抗性前立腺がん前後の治療パターン。

対象DB：MDV

32. Safety and efficacy of day-case hip and knee arthroplasty in the NHS: a nationwide UK cohort study.

英国における日帰り股関節・膝関節置換術の安全性と有効性を評価。

対象DB：CPRD

33. Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.

動脈硬化性心血管疾患患者における心不全発症予測モデルの構築。

対象DB：CPRD

34. The role of COPD and inhaled corticosteroids in major adverse cardiovascular events in cardiovascular-kidney-metabolic populations.

循環器疾患患者の心血管事象におけるCOPDと吸入ステロイドの影響。

対象DB：CPRD

35. Nationwide trends in physician consultation and surgical management for pelvic organ prolapse in Japan, 2014 to 2024: a health insurance claims database analysis.

日本における骨盤臓器脱の受診と手術管理の全国的な傾向。

対象DB：DeSC